ID   KBM-7/B5-1803
AC   CVCL_8Z14
SY   KBM7-B5-1803; KBM-7/B5 clone 1803
DR   cancercelllines; CVCL_8Z14
DR   Wikidata; Q54899588
RX   PubMed=9783811;
CC   Group: Haploid karyotype cell line.
CC   Karyotypic information: Haploid except for a disomy of chromosome 8.
CC   Selected for resistance to: ChEBI; CHEBI_4027; Cyclophosphamide (CP; Endoxan).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 13 fused to ABL1 exon 2 (b2a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B254 ! KBM-7/B5
SX   Male
AG   40Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 19-12-24; Version: 17
//
RX   PubMed=9783811; DOI=10.1016/S0145-2126(98)00093-9;
RA   Munker R., Zhao S.-R., Jiang S.-W., Snell V., Andreeff M.,
RA   Andersson B.S.;
RT   "Further characterization of cyclophosphamide resistance: expression
RT   of CD95 and of bcl-2 in a CML cell line.";
RL   Leuk. Res. 22:1073-1077(1998).
//